Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.
Department of Oncology, University Hospital Grenoble, Grenoble, France. apirvu@chu-grenoble.fr
Oana
O
Pop
Augustin
A
Pirvu
Anne-Claire
AC
Toffart
Denis
D
Moro-Sibilot
D000008:Abdominal Neoplasms / Q000139:chemically induced* / Q000532:radiotherapy; D000359:Aftercare; D001932:Brain Neoplasms / Q000139:chemically induced* / Q000532:radiotherapy; D000077547:Crizotinib; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*
C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib